Fig. 1: SHANK3 depletion inhibits cell proliferation in vitro and in vivo in different cancer types driven by distinct KRAS mutations.
From: SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers
a A cell proliferation screen following control (siCTRL, grey) or SHANK3 silencing (siSHANK3_2 (red) or siSHANK3_7 (blue)) in wild-type (WT) or KRAS-mutant pancreatic (PDAC), lung (NSCLC) and colorectal (CRC) cancer cell lines. ARPE-19, non-transformed retinal epithelial cells. Shown are the individual data points relative to control [the mean of the control is set to 1.0 by definition; data are mean ± s.d.; n = 3 (Panc10.05 siCTRL and H226 siSHANK3_2) or 4 (other samples) individually silenced wells; two-way ANOVA with Dunnett’s multiple comparisons test]. b Spheroid growth of siCTRL or siSHANK3 PANC-1 or A549 cells. Shown are representative images and quantification of spheroid area (mean ± s.d.; n = 3 independent experiments; statistical analysis at end point, one-way ANOVA with Holm-Sidak’s multiple comparison test). c–e Analysis of siCTRL or siSHANK3 PANC-1 and A549 tumour growth on chorioallantoic membranes (CAMs). c Immunoblots showing SHANK3 protein levels in cell suspensions inoculated onto the CAMs [n = 1 (PANC1) and 2 (A549) independent experiments], (d) tumour weights, and (e) representative immunostainings and quantification of Ki-67-positive cells in tumours. Shown are individual data points [mean ± s.d.; n = 17 (PANC-1 siCTRL), 23 (PANC-1 siSHANK3), 27 (A549 siCTRL) or 22 (A549 siSHANK3) (d) and 9 (PANC-1) or 10 (A549) (e) tumours per sample group from 1 (PANC-1) or 2 (A549) independent experiments; two-way ANOVA with Mann–Whitney test (d) and Unpaired two-tailed Student’s t-test with Welch’s correction (e)]. Source data are provided as a Source Data file.
